Biosynex (PA:ALBIO) — Stock Price
Biosynex (PA:ALBIO) is currently trading at €0.91 EUR, up 0.66% today. Over the past 52 weeks, shares have ranged between €0.48 and €1.57. This page tracks Biosynex's live share price on the PA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Biosynex stock valuation.
Biosynex (ALBIO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Biosynex's daily closing share price and trading volume on the PA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Biosynex Income Statement — Revenue, Profit & Earnings by Year
Biosynex's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €101.20 Million | €92.98 Million | €196.59 Million | €382.53 Million | €153.90 Million |
| Cost of Revenue | €43.75 Million | €43.85 Million | €132.07 Million | €199.98 Million | €105.80 Million |
| Gross Profit | €-20.00 Million | €49.13 Million | €64.52 Million | €182.55 Million | €48.10 Million |
| Research & Development | — | €3.92 Million | €2.85 Million | — | — |
| SG&A | €42.44 Million | €37.01 Million | €57.02 Million | €58.06 Million | €31.69 Million |
| Total Operating Expenses | €93.75 Million | €86.54 Million | €63.44 Million | €65.76 Million | €23.58 Million |
| Operating Income | €-21.10 Million | €-37.40 Million | €38.86 Million | €140.65 Million | €45.73 Million |
| EBITDA | €-17.83 Million | €-10.18 Million | €46.73 Million | €146.60 Million | €51.30 Million |
| EBIT | €-23.20 Million | €-34.80 Million | €30.36 Million | €139.99 Million | €44.66 Million |
| Interest Expense | €6.20 Million | €2.64 Million | €501.00K | €365.47K | €224.32K |
| Income Before Tax | €-38.43 Million | €-39.68 Million | €24.18 Million | €136.94 Million | €43.52 Million |
| Income Tax Expense | €-1.40 Million | €-2.56 Million | €8.57 Million | €32.94 Million | €12.15 Million |
| Net Income | €-43.30 Million | €-36.95 Million | €15.66 Million | €104.00 Million | €31.37 Million |
Biosynex Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Biosynex's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €194.69 Million | €241.73 Million | €259.98 Million | €268.94 Million | €126.07 Million |
| Total Current Assets | €64.39 Million | €91.35 Million | €159.24 Million | €198.78 Million | €87.53 Million |
| Cash & Equivalents | — | — | — | — | €0.00 |
| Short-term Investments | €5.00 Million | €6.00 Million | €1.00 | €2.42 Million | €5.18 Million |
| Net Receivables | €10.90 Million | €10.65 Million | €14.70 Million | €34.67 Million | €11.49 Million |
| Inventory | €32.66 Million | €38.21 Million | €37.67 Million | €31.15 Million | €32.55 Million |
| Property, Plant & Equipment | €14.85 Million | €16.10 Million | €8.74 Million | €5.26 Million | €2.36 Million |
| Goodwill | €64.13 Million | €91.54 Million | €60.91 Million | €46.24 Million | €29.27 Million |
| Total Liabilities | €114.19 Million | €117.41 Million | €93.21 Million | €101.14 Million | €59.78 Million |
| Total Current Liabilities | €85.98 Million | €40.82 Million | €39.50 Million | €52.91 Million | €45.96 Million |
| Long-term Debt | €14.35 Million | €58.28 Million | €49.52 Million | €34.27 Million | €15.72 Million |
| Net Debt | €57.77 Million | €45.43 Million | €-35.10 Million | €-96.72 Million | €-21.07 Million |
| Total Stockholder Equity | €80.58 Million | €124.48 Million | €162.40 Million | €167.81 Million | €66.29 Million |
| Retained Earnings | €73.80 Million | €55.31 Million | €76.97 Million | €130.83 Million | €31.37 Million |
Biosynex Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Biosynex generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-10.12 Million | €-9.65 Million | €4.95 Million | €109.83 Million | €31.64 Million |
| Capital Expenditures | €4.84 Million | €39.54 Million | €30.08 Million | €19.02 Million | €9.12 Million |
| Free Cash Flow | €-14.96 Million | €-49.20 Million | €-25.13 Million | €90.82 Million | €22.52 Million |
| Investing Cash Flow | €-4.60 Million | €-54.81 Million | €-39.08 Million | €-28.96 Million | €-7.93 Million |
| Financing Cash Flow | €-801.00K | €5.17 Million | €-10.81 Million | €14.40 Million | €10.62 Million |
| Dividends Paid | — | — | €-20.44 Million | €22.31 Million | €1.94 Million |
| Stock-Based Compensation | — | — | €-32.74 Million | €-504.23K | €-13.28 Million |
| Depreciation | €20.53 Million | €13.46 Million | €21.36 Million | €2.04 Million | €7.25 Million |
| Change in Cash | €-15.52 Million | €-59.30 Million | €-44.86 Million | €95.27 Million | €34.99 Million |
Biosynex Earnings History — EPS Actual vs. Analyst Estimates
Track Biosynex's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Oct 30, 2025 | -2.59 | 0.00 | — |
| Apr 30, 2025 | -2.08 | 0.00 | — |
| Nov 03, 2024 | -1.95 | 0.00 | — |
| Oct 20, 2022 | 2.97 | — | — |
| Apr 22, 2022 | 2.76 | 0.00 | — |
| Apr 29, 2021 | 2.40 | 0.00 | — |
| Dec 01, 2020 | 0.65 | 0.00 | — |
| May 04, 2020 | 0.06 | 0.00 | — |